Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis

Area of Science:

• Intensive Care Medicine
• Cardiology
• Pulmonology

Background:

• Severe COVID-19 pneumonia poses a significant clinical challenge, necessitating intensive care.
• Dexamethasone has shown promise in reducing mortality rates for severe COVID-19.
• The impact of dexamethasone on cardiac injury and pulmonary embolism in these patients requires further elucidation.

Purpose of the Study:

• To investigate the effects of dexamethasone treatment on cardiac injury and pulmonary embolism in critically ill COVID-19 patients.
• To assess the association between dexamethasone's anti-inflammatory properties and myocardial injury.
• To evaluate the antithrombotic effects of dexamethasone in severe COVID-19.

Main Methods:

• Retrospective study involving 178 critically ill COVID-19 patients requiring mechanical ventilation across three European centers.
• 113 patients received dexamethasone for a median of 10 days; 65 served as a control group.
• Analysis focused on inflammatory markers, troponin levels, D-Dimer levels, and pulmonary embolism rates.

Main Results:

• Dexamethasone treatment significantly reduced peak troponin levels (myocardial injury marker) and peak D-Dimer levels (thrombosis marker).
• A significant reduction in pulmonary embolism rates was observed in the dexamethasone group (4.4% vs. 20.0%).
• This beneficial antithrombotic effect was evident even with therapeutic anticoagulation, and no baseline characteristic differences were noted between groups.

Conclusions:

• Dexamethasone's anti-inflammatory effects in severe COVID-19 are linked to reduced myocardial injury.
• Dexamethasone significantly decreases the incidence of pulmonary embolism, independent of anticoagulation status.
• The findings emphasize the multifaceted benefits of dexamethasone in managing severe COVID-19 patients.